当前位置: 首页 >> 检索结果
162. Budesonide-formoterol versus salbutamol as reliever therapy in children with mild asthma (CARE): a 52-week, open-label, multicentre, superiority, randomised controlled trial.
作者: Lee Hatter.;Mark Holliday.;Karen Oldfield.;Ciléin Kearns.;Tasmin Barry.;Melissa Black.;Pepa Bruce.;Atalie Colman.;Emily Dickinson.;Allie Eathorne.;Matire Harwood.;Thomas Hills.;Rebekah Lamb.;Kyley Kerse.;Srinidhi Krishnamoorthy.;John Martindale.;Alex Semprini.;Nick Shortt.;David McNamara.;Catherine A Byrnes.;Stuart R Dalziel.;Andrew Bush.;Mark Weatherall.;Richard Beasley.; .
来源: Lancet. 2025年406卷10511期1473-1483页
Combination inhaled corticosteroid-formoterol reliever monotherapy reduces the rate of asthma attacks compared to short-acting β2-agonist (SABA) reliever monotherapy in adults. Its comparative efficacy in children has not been established.
163. Availability of essential medicines in 14 remaining health facilities in Gaza.
作者: Saleh Aljadeeah.;Gautam Satheesh.;Sali Hafez.;Mina Naguib.;Amy Neilson.;Asil Alaloul.;Gorik Ooms.;Duha Shellah.;Bissan Ismail Abu Shammala.;Raffaella Ravinetto.
来源: Lancet. 2025年406卷10511期1465-1467页 164. A clinical decision tool including a decision tree, point-of-care testing of CRP, and safety-netting advice to guide antibiotic prescribing in acutely ill children in primary care in Belgium (ARON): a pragmatic, cluster-randomised, controlled trial.
作者: Jan Yvan Verbakel.;Ruben Burvenich.;Erinn D'hulster.;Liselore De Rop.;Ann Van den Bruel.;Sibyl Anthierens.;Samuel Coenen.;An De Sutter.;Stefan Heytens.;Louise Joly.;Marina Digregorio.;Annouschka Laenen.;Jeroen Luyten.;Tine De Burghgraeve.
来源: Lancet. 2025年406卷10512期1599-1610页
Antimicrobial resistance is a global health threat. Many children with acute illness in ambulatory care are unnecessarily prescribed antibiotics. We assessed the clinical effectiveness of a clinical decision tool for these children, including a validated decision tree, guided point-of-care C-reactive protein testing (POCT of CRP), and safety-netting advice.
165. Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study.
作者: David Kavanagh.;Andrew S Bomback.;Marina Vivarelli.;Carla M Nester.;Giuseppe Remuzzi.;Ming-Hui Zhao.;Edwin K S Wong.;Yaqin Wang.;Induja Krishnan.;Imelda Schuhmann.;Angelo J Trapani.;Nicholas J A Webb.;Matthias Meier.;Rubeen K Israni.;Richard J H Smith.; .
来源: Lancet. 2025年406卷10512期1587-1598页
C3 glomerulopathy is an ultra-rare, severe form of glomerulonephritis caused by overactivation of the alternative complement pathway. We aimed to assess efficacy and safety of iptacopan (LNP023), an oral, proximal complement inhibitor that targets factor B to selectively inhibit the alternative pathway of the complement cascade.
|